Brokers Issue Forecasts for Altimmune FY2029 Earnings

Altimmune, Inc. (NASDAQ:ALT) – HC Wainwright issued their FY2029 earnings per share estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $1.30 for the year. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

A number of other equities analysts also recently commented on the company. Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. UBS Group initiated coverage on Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.83.

Altimmune Stock Performance

NASDAQ:ALT opened at $6.98 on Monday. The stock has a 50-day simple moving average of $7.88 and a 200 day simple moving average of $7.20. Altimmune has a one year low of $5.28 and a one year high of $14.84. The company has a market capitalization of $496.42 million, a price-to-earnings ratio of -4.50 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the business posted ($0.39) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALT. Dimensional Fund Advisors LP grew its position in Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares during the last quarter. Bellevue Group AG grew its position in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after purchasing an additional 263,660 shares in the last quarter. Virtu Financial LLC purchased a new position in Altimmune during the 3rd quarter worth approximately $674,000. Exchange Traded Concepts LLC grew its position in Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after purchasing an additional 92,498 shares in the last quarter. Finally, Barclays PLC grew its position in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after purchasing an additional 75,064 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.